Integrated QC As A Development Strategy: Reducing Late-Stage Analytical Risk

In early clinical manufacturing, quality control is often treated as a downstream testing function that becomes prominent only when validation, release testing, or stability execution is already on the critical path. The poster argues for a different model: integrate QC into the project from the beginning so analytical readiness develops in parallel with formulation and manufacturing readiness. At the Bend Bioscience Oregon site, Product Development and GMP Analytical teams share method history, validation expectations, instrumentation platforms where applicable, and ongoing technical collaboration. Development data is deliberately used to shape validation design, while QC-owned execution formalizes suitability when required. Validation pathways are matched to the method, phase, and project need, including both SOP-based and protocol-driven approaches, with a phase-appropriate objective of enabling release and Certificate of Analysis issuance while maintaining a defined path to later-phase readiness. Analytical risks are tracked in living project reporting alongside formulation, stability, and manufacturability risks rather than being discovered during release. Digital planning and ELN infrastructure improve visibility into sample management, stability pulls, execution status, and dependencies. When issues arise, investigations draw on cross-functional expertise from QC, Product Development, and other SMEs to preserve product knowledge and accelerate root-cause understanding. The result is a model in which QC contributes to development decisions rather than simply testing the final output, reducing late surprises and supporting more predictable clinical supply timelines.